BACKGROUND: In the United States, implementation of the seven‐valent conjugate vaccine
into childhood immunization schedules has had an effect on the burden of pneumococcal …

The objective of this study was to evaluate the projected health benefits, costs, and cost-
effectiveness of pneumococcal conjugate vaccination for infants and children aged< 5 years …

In the year 2000, a heptavalent pneumococcal conjugate vaccine (PCV7) was licensed and
recommended for routine immunization of infants in the USA. During the following years, a …

Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the
United States since 2000 and data have indicated direct and indirect effects of the vaccine …

Objective. To evaluate the impact of the introduction and routine use of seven valent
pneumococcal conjugate vaccine on the epidemiology of invasive pneumococcal disease …

Introduction Despite the availability of vaccines, pneumococcal disease (PD) is associated
with high clinical and economic burden, mainly caused by non-vaccine serotypes and …

In February 2000, a heptavalent pneumococcal conjugate vaccine (PCV7 [Prevnar]) was
licensed in the United States for administration to children younger than 5 years of age. The …

In the province of Quebec, Canada, the pneumococcal 7-valent conjugate vaccine (PCV-7)
was licensed in 2001 and a publicly funded program was implemented in 2004 …

Streptococcus pneumoniae (pneumococcus) is a leading cause of pneumonia and
meningitis in the United States and disproportionately affects young children and the elderly …

Background: In Canada, a pneumococcal conjugate vaccine was licensed in 2001, and in
the province of Quebec, a publicly-funded program was implemented for high-risk children …